Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR00208 (tafasitamab) with idelalisib or venetoclax in BTK inhibitor–pretreated relapsed/refractory CLL/SLL
2015-002915-14Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tafasitamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by MorphoSys AG. Primary endpoint: Incidence and severity of adverse events. Started Oct 2015; status: completed.
02
Drugs
tafasitamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-002915-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002915-14.